SOURCE: Medivisor Inc.

September 16, 2008 08:40 ET

Medivisor Inc. Announces Update on LIPIDEME™

HUNTINGTON STATION, NY--(Marketwire - September 16, 2008) - Medivisor, Inc. (PINKSHEETS: MVSR) announced today that it intends to increase awareness for LIPIDEME™ in Italy. LIPIDEME™ is a synergistic blend of ingredients designed to lower cholesterol four ways. Since signing the initial revenue sharing agreement with PanGenex Corporation, Medivisor has gathered initial interest for the product and expects to begin shipping samples later in the month.

"With an abundance of people worldwide currently take cholesterol lowering medication, and LIPIDEME™ addressing the need of those consumers, we feel the market potential for this product is enormous," said Dino Luzzi, CEO of Medivisor, Inc. "We have garnered strong LIPIDEME™ interest from Italy, and once received from Pangenex, will be sending samples to a major Italian distributor," furthered Mr. Luzzi.

Under its recently announced revenue sharing agreement with PanGenex Corporation, Medivisor is responsible for generating sales growth for LIPIDEME™ through both US and international distribution channels. The American Heart Association estimates that nearly 140 million Americans have either borderline-high or high cholesterol, as determined by a blood test called a lipid panel. In 2003, approximately 22 million people took a medication to try to lower their cholesterol. LIPIDEME™ is positioned as an all-natural product to address high cholesterol from a dietary and genetic standpoint.

About Medivisor Inc.:

Medivisor, Inc., a rapidly growing developer of next-generation focus driven marketing tools. The company is dedicated to providing technologies that offer innovative and competitive advantages to the bioscience and pharmaceutical markets and beyond. From pre-product development through product launch and commercialization, Medivisor offers worldwide experience in delivering effective and successful integrated marketing and creative communications campaigns for the mutual benefit of its clients.

About PanGenex Corporation:

PanGenex is a publicly traded corporation and pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as, and

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the performance ability of the initial units in the field. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission. Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact Information

  • Contact:
    Dino Luzzi
    Medivisor, Inc.
    326 Walt Whitman Road
    Huntington Station, N.Y. 11746
    Tel: 631.549.7100